

Fig. 2 Flow chart 2: treatment of borderline epithelial ovarian tumors. *Fertility-preserving surgery—affected-side salpingo-oophorectomy + omentectomy + peritoneal cytology + detailed intra-abdominal examination

CQ 27: What chemotherapy regimen is recommended for recurrence after a DFI of ≥ 6 months?

Recommendations

Combination therapy including a platinum agent is strongly recommended (Grade A).

CQ 28: What are the indications and strategy for secondary debulking surgery (SDS) in patients with recurrence?

Recommendations

- (1) Whether or not SDS is worth performing should be carefully determined by evaluating the timing of recurrence, the primary surgical procedure, the site of recur-

rence, the number of lesions, and the performance status of the patient in a comprehensive manner (Grade C1).

- (2) When SDS is performed, the objective should be complete resection of the tumor when possible (Grade C1).

CQ 29: What are the indications for radiation therapy in patients with recurrence?

Recommendations

- (1) Radiation therapy should be considered in order to relieve symptoms, such as pain and bleeding (Grade C1).
- (2) Radiation therapy should be considered for brain metastasis, not only to relieve symptoms, but also to prolong survival (Grade C1).




Fig. 3 Flow chart 3: treatment of recurrent epithelial ovarian cancer

CQ 30: What is the recommended management strategy for intestinal obstruction and accumulation of ascites?

Recommendations

Intestinal obstruction

- (1) Administration of octreotide is strongly recommended for nausea/vomiting (Grade A).
- (2) Correcting physical obstruction by palliative surgery is recommended for relieving nausea/vomiting (Grade B).
- (3) Administration of corticosteroids should be considered to relieve nausea/vomiting (Grade C1).

Accumulation of ascites

- (1) In patients with terminal cancer whose life expectancy is estimated to be $\leq 1-2$ months, the volume of infusion solution should be limited to $\leq 1,000$ mL/day if the patient has pain due to accumulation of ascites (Grade C1).
- (2) Taking the underlying pathological state into consideration, administration of diuretics, drainage of ascitic fluid (paracentesis), creation of a peritoneovenous shunt, and cell-free and concentrated ascites reinfusion

therapy should be considered for relieving pain due to accumulation of ascites (Grade C1).

Chapter 5: Primary peritoneal cancer/fallopian tube cancer

Treatment of primary peritoneal cancer or fallopian tube cancer is summarized as flow chart 4 (Fig. 4).

CQ 31: What is the optimal surgical procedure for primary peritoneal cancer?

Recommendations

Maximal debulking surgery to accomplish complete resection (no gross residual tumor) should be considered (Grade C1).

CQ 32: What chemotherapy regimen is recommended for primary peritoneal cancer?

Recommendations

- (1) Either conventional TC therapy or dose-dense TC therapy should be considered (Grade C1).




Fig. 4 Flow chart 4: treatment of primary peritoneal cancer and fallopian tube cancer

(2) Neoadjuvant chemotherapy should also be considered (Grade C1).

CQ 33: What is the optimal surgical procedure for fallopian tube cancer?

Recommendations

- (1) According to the procedure for treating ovarian cancer, bilateral salpingo-oophorectomy + total hysterectomy + omentectomy are recommended together with peritoneal cytology + pelvic/para-aortic lymph node dissection (biopsy) + biopsies from sites in the abdominal cavity (Grade B).
- (2) Maximal debulking surgery to accomplish complete resection (no gross residual tumor) is recommended for patients with advanced cancer (Grade B).

CQ 34: What chemotherapy regimen is recommended for fallopian tube cancer?

Recommendations

Conventional TC therapy or dose-dense TC therapy should be considered (Grade C1).

Chapter 6: Malignant ovarian germ cell tumors

Treatment of malignant ovarian germ cell tumors is summarized as flow chart 5 (Fig. 5).

CQ 35: What is the optimal surgical procedure for malignant ovarian germ cell tumors?

Recommendations

- (1) For patients who wish to preserve fertility, in addition to salpingo-oophorectomy on the affected side + omentectomy + peritoneal cytology, detailed intra-abdominal examination is recommended (Grade B).
- (2) For patients who do not require preservation of fertility, according to the procedure for treating ovarian cancer, bilateral salpingo-oophorectomy + total hysterectomy + omentectomy are recommended together with peritoneal cytology, pelvic/para-aortic lymph node dissection (biopsy), and biopsies from sites in the abdominal cavity. However, lymph node dissection (biopsy) can be omitted (Grade B).
- (3) For patients with advanced cancer, maximal debulking surgery to accomplish complete resection (no




Fig. 5 Flow chart 5: treatment of malignant germ cell tumors. *Fertility-preserving surgery—affected-side salpingo-oophorectomy + omentectomy + peritoneal cytology + detailed intra-abdominal examination. **Lymph node dissection (biopsy) can be omitted

gross residual tumor) is recommended. However, lymph node dissection (biopsy) can be omitted (Grade B).

CQ 36: What postoperative treatment is recommended for malignant ovarian germ cell tumors?

Recommendations

Chemotherapy using bleomycin, etoposide, and cisplatin (BEP therapy) is strongly recommended (Grade A).

CQ 37: What treatment is recommended for recurrence of malignant ovarian germ cell tumors after first-line chemotherapy?

Recommendations

- (1) Combination chemotherapy using cisplatin, such as a triple-drug combination of cisplatin with two other drugs (from among ifosfamide, etoposide, vinblastine, and/or paclitaxel), should be considered (Grade C1).
- (2) SDS can be considered for some patients (Grade C1).

CQ 38: What should be kept in mind during follow-up after treatment of malignant ovarian germ cell tumors?

Recommendations

- (1) You should be mindful that ovarian dysfunction may occur (Grade C1).
- (2) When etoposide has been administered, you should consider that secondary cancer may occur (Grade C1).

Chapter 7: Malignant sex cord-stromal tumors

Treatment of malignant sex cord-stromal tumors is summarized as flow chart 6 (Fig. 6).

CQ 39: What is the optimal surgical procedure for malignant sex cord-stromal tumors?

Recommendations

- (1) According to the procedure for treating ovarian cancer, bilateral salpingo-oophorectomy + total hysterectomy




Fig. 6 Flow chart 6: treatment of malignant sex cord-stromal tumors. *Fertility-preserving surgery—affected-side salpingo-oophorectomy + omentectomy + peritoneal cytology + detailed intra-abdominal examination. **Lymph node dissection (biopsy) can be omitted

tomy + omentectomy are recommended together with peritoneal cytology, pelvic/para-aortic lymph node dissection (biopsy), and biopsies from sites in the abdominal cavity. However, lymph node dissection (biopsy) can be omitted (Grade C1).

- (2) For patients who wish to preserve fertility, in addition to affected-side salpingo-oophorectomy + omentectomy + peritoneal cytology, detailed intra-abdominal examination should be considered (Grade C1).

CQ 40: What postoperative treatment is recommended for malignant sex cord-stromal tumors?

Recommendations

- (1) With regard to chemotherapy, a platinum-containing regimen should be considered (Grade C1).
 (2) Radiotherapy should also be considered (Grade C1).

CQ 41: What is important during follow-up after treatment of malignant sex cord-stromal tumors?

Recommendations

Management should be performed according to the protocol for ovarian cancer. Additionally, long-term follow-up for at least 10 years after treatment should be considered for granulosa cell tumors (Grade C1).

Acknowledgments Creation of this guideline was supported by the Japan Society of Gynecologic Oncology with contributions from “Encouragement of wider use of practice guidelines for cancer and their effects, as well as investigation of guideline projects” (chief investigator: Koichi Hirata), Research for Promotion of Cancer Control Programmes (2014), and a Health and Labour Sciences Research

Grant. The funding sources did not influence the contents of this guideline.

Conflict of interest The conflict-of-interest committee of the Japan Society of Gynecologic Oncology checked conflicts of interest for the people involved in creating and evaluating this guideline and their associates (i.e., marital partner, first-degree relatives, or people sharing income/assets), according to the “Guidelines for conflict of interest issues in clinical studies on cancer” (<http://www.jsgo.or.jp/topics/index01.html>) published by the Japan Society of Gynecologic Oncology. Although there were conflicts of interest for some contributors through research/lecture activities supported by companies, the recommendations in this guideline are based on scientific evidence and have not been influenced by the interests of a specific organization and are not biased in recommending or products or techniques.

Guidelines for treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer 2015 (4th edition)

Guideline development committee

Mitsuya Ishikawa, Fumiaki Isohashi, Yoshio Itani, Kimihiko Ito, Masahiro Iwasaki, Yasuhiko Ebina, Yoshihiro Ohishi, Hideyuki Ohtake, Tatsuru Oohara, Hiroaki Kajiyama, Noriyuki Katsumata, Kazuyoshi Kato, Shingo Kato, Masanori Kanemura, Kei Kawana, Takako Kiyokawa, Keisuke Kurose, Shinichi Komiyama, Kimiko Sato, Morio Sawada, Tadahiro Shoji, Masashi Takano, Hiroshi Tanabe, Hiroshi Tsubamoto, Fumitoshi Terauchi, Yasuhisa Terao, Kimihiro Nagai, Yoshifumi Nakao, Satoru Nagase, Kentaro Nakayama, Koji Nishino, Hiroyuki Nomura, Kazuhiko Hayashi, Eiji Hirata, Kiyoshi Fujiwara, Hiroyuki Fujiwara, Masayuki Futagami, Yusuke Matsuura, Noriomi Matsumura, Koji Matsumoto, Yoshiki Mikami, Yo Miyahara, Toshinari

Muramatsu, Hidekazu Yamada, Kiyoshi Yoshino, Yoshimitsu Ryo, and Hidemichi Watari (in order of the Japanese syllabary).

Guideline review committee

Satomi Aihara, Daisuke Aoki, Yoichi Aoki, Seiji Isonishi, Hiroaki Itamochi, Kazuhiko Ino, Osamu Iwanari, Kimio Ushijima, Masahide Ohmichi, Kazunori Ochiai, Takashi Onda, Hidenori Kato, Junzo Kigawa, Satoru Kyo, Hiroyuki Kuramoto, Hiroaki Kobayashi, Tsuyoshi Saito, Noriaki Sakuragi, Toyomi Satoh, Kiyosumi Shibata, Toru Sugiyama, Mitsuaki Suzuki, Kazuhiro Takehara, Shinichi Tate, Tsutomu Tabata, Katsuhiro Teramoto, Takafumi Toita, Takafumi Nakamura, Kaei Nasu, Toru Hachisuga, Kenichi Harano, Fumiki Hirahara, Ichio Fukasawa, Keiichi Fujiwara, Satoru Makinoda, Koji Miyazaki, Masanori Yasuda, Yoshihito Yokoyama, Hiroyuki Yoshikawa, and Kosuke Yoshinaga (in order of the Japanese syllabary).

References

1. Cancer Mortality in Japan (2012) Center for Cancer Control and Information Services. National Cancer Center, Japan. <http://ganjoho.jp/professional/statistics/statistics.html>. Accessed 15 Sept 2014
2. Heintz AP, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. *Int J Gynaecol Obstet* 95(Suppl 1):S161–S192
3. Gynecologic Cancer Committee (2012) Gynecologic cancer committee report in 2011. *Acta Obstet Gynaecol Jpn* 66:1024–1038
4. Ariyoshi H (2002) Guideline for correct use of antineoplastic agents (draft). General theory. *Gan To Kagaku Ryoho* 29:970–977
5. Ochiai K, Okamoto A, Katsumata N (2002) Guidelines for proper use of antineoplastic agents. *Gynecologic cancer. Gan To Kagaku Ryoho* 29:1047–1054
6. Fukui T, Yoshida M, Yamaguchi N (2007) *Minds Guidance of practice guidelines 2007*. Igakushoin, Tokyo
7. Takeuchi H, Saeki T, Aiba K et al (2016) Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. *Int J Clin Oncol* 21:1–12
8. Japanese Society of Clinical Oncology clinical practice guidelines 2013 for G-CSF. <http://www.jscocp-jp/item/30/index.html>

Japan Society of Gynecologic Oncology guidelines 2013 for the treatment of uterine body neoplasms

Yasuhiko Ebina¹ · Hidetaka Katabuchi² · Mikio Mikami³ · Satoru Nagase⁴ ·
Nobuo Yaegashi⁵ · Yasuhiro Udagawa⁶ · Hidenori Kato⁷ · Kaneyuki Kubushiro⁸ ·
Kiyoshi Takamatsu⁹ · Kazuhiko Ino¹⁰ · Hiroyuki Yoshikawa¹¹

Received: 25 March 2016 / Accepted: 3 April 2016
© Japan Society of Clinical Oncology 2016

Abstract The third version of the Japan Society of Gynecologic Oncology guidelines for the treatment of uterine body neoplasms was published in 2013. The guidelines comprise nine chapters and nine algorithms. Each chapter includes a clinical question, recommendations, background, objectives, explanations, and references. This revision was intended to collect up-to-date international evidence. The highlights of this revision are to (1) newly specify costs and conflicts of interest; (2) describe the clinical significance of pelvic lymph node dissection and para-aortic lymphadenectomy, including variant histologic types; (3) describe more clearly the indications for laparoscopic surgery as the standard treatment; (4) provide guidelines for post-treatment hormone replacement therapy; (5) clearly differentiate treatment of advanced or recurrent cancer between the initial treatment and the treatment carried out after the primary operation; (6) collectively describe fertility-sparing therapy for both atypical endometrial hyperplasia and

endometrioid adenocarcinoma (corresponding to G1) and newly describe relapse therapy after fertility-preserving treatment; and (7) newly describe the treatment of trophoblastic disease. Overall, the objective of these guidelines is to clearly delineate the standard of care for uterine body neoplasms in Japan with the goal of ensuring a high standard of care for all Japanese women diagnosed with uterine body neoplasms.

Keywords Clinical practice guidelines · Endometrial cancer · Treatment · Trophoblastic disease · Uterine sarcoma

Introduction

Endometrial cancer is one of the most common malignancies of the female genital tract. In Japan, the age-adjusted incidence rate of endometrial cancer was 17.2 (per 100,000 women) in 2011, indicative of a four- to five-fold increase over the past three decades [1]. It is estimated

This article originally appeared in Japanese as *Shikyu taigan chiryo guidorain 2013 nen ban*, published by Kanehara, Tokyo, 2013.

✉ Yasuhiko Ebina
ebiyas@med.kobe-u.ac.jp

¹ Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan

² Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

³ Department of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara, Japan

⁴ Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata, Japan

⁵ Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan

⁶ Fujita Health University School of Medicine, Toyoake, Japan

⁷ Division of Gynecologic Oncology, National Hospital Organization, Hokkaido Cancer Center, Sapporo, Japan


⁸ Department of Obstetrics and Gynecology, Toho University School of Medicine, Toho University Medical Center Ohashi Hospital, Tokyo, Japan

⁹ Department of Obstetrics and Gynecology, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Chiba, Japan

¹⁰ Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Japan

¹¹ Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Published online: 26 April 2016

 Springer

that 10,300 new uterine cancer cases occurred in 2014 [2], with 2,243 deaths resulting from the disease [1]. Surgery, chemotherapy, radiation, and hormone therapy are used either alone or sequentially to treat endometrial cancer. Surgery is recommended for medically operable disease. When the disease is limited to the uterus, then hysterectomy, bilateral salpingo-oophorectomy, and pelvic/para-aortic lymph node dissection are recommended. However, whether to add para-aortic lymphadenectomy to pelvic node dissection remains controversial. Furthermore, there are differences in the adjuvant therapies employed in Japan and in Western countries. In Western countries, radiation therapy is the mainstay of postoperative adjuvant therapy, whereas in Japan, chemotherapy is more frequently performed. These differences are one reason why evidence from Western countries cannot be directly applied to the development of recommendations for Japanese patients. Under such circumstances, the first edition of the Japan Society of Gynecologic Oncology (JSGO) guidelines for the treatment of endometrial cancer was published in 2006 and revised in 2009 [3]. The second revised version contained two new sections—the treatment of mesenchymal tumors such as leiomyosarcoma and the treatment of serous and clear-cell adenocarcinoma [3].

The third edition of the JSGO guidelines for the treatment of uterine body neoplasms was published in 2013. The guidelines comprise nine chapters and nine algorithms. The highlights of this revision are indicated below.

1. Chapter 1: Overview of guidelines. New specification of costs and conflicts of interests are identified.
2. Chapter 2: Initial treatment for endometrial cancer. The clinical significance of pelvic lymph node dissection and para-aortic lymphadenectomy, including variant histologic types, are described in detail. An additional indication for laparoscopic surgery as the standard treatment is also described more clearly. Finally, the optimal treatment for patients in whom it is evident that endometrial cancer is present after hysterectomy is also described.
3. Chapter 3: Postoperative adjuvant therapy for endometrial cancer. Chemotherapy is described as having priority over radiation therapy in line with the present conditions in Japan, including the above-mentioned variant histologic type.
4. Chapter 4: Post-treatment surveillance for endometrial cancer. The guidelines for hormone replacement therapy after treatment are described first based on “The Guidelines for Hormone Replacement Therapy 2012,” edited by the Japan Society of Obstetrics and Gynecology (JSOG) and the Japan Society for Menopause and Women’s Health.
5. Chapter 5: Treatment for advanced or recurrent endometrial cancer. The difference between the initial treatment and the treatment carried out after the primary operation is clearly described.
6. Chapter 6: Fertility-sparing therapy. Two diseases, namely atypical endometrial hyperplasia and endometrioid adenocarcinoma (corresponding to G1), are collectively described. Relapse therapy after the fertility-preserving treatment is also newly described.
7. Chapter 7: Treatment of uterine carcinosarcoma and uterine sarcoma. This chapter was first included in the 2009 version. In addition, chapter 8 “Treatment of trophoblastic disease” is newly described to support “the general roles for clinical and pathological management of trophoblastic diseases (the third edition)”.

Chapter 1: Overview of guidelines

1. How to use these guidelines

These guidelines are intended for doctors (general practitioners and specialists) who provide medical care for patients with uterine tumors and are meant to provide useful treatment methods by integrating previous evidence of benefit. However, the guidelines are not intended to be limited to the therapies listed. The main purposes of the guidelines are (1) to indicate current treatment that is considered appropriate for endometrial cancer, carcinosarcoma/sarcoma, and trophoblastic diseases; (2) to reduce differences in therapy among institutions; (3) to improve the prognosis and safety of treatments; (4) to reduce the economic and psychosomatic burden of patients by promoting the performance of appropriate treatment; and (5) to aid mutual understanding of healthcare professionals and patients.

2. Intended audience

These guidelines are intended for practicing physicians engaged in the treatment of patients with endometrial cancer, carcinosarcoma/sarcoma, and trophoblastic diseases.

3. Diseases addressed by these guidelines

Endometrial cancer was mainly described in the first edition. Variant histologic types of uterine cancer and carcinosarcoma/sarcoma were added in the revised edition. Trophoblastic disease was added to the latest revised edition, and these tumors and their recurrence are described in these guidelines. The characteristics of these guidelines are as follows. Initial, postoperative and advanced/recurrent treatment of variant histologic type was discussed

Table 1 Classification of evaluation criteria for evidence quality

<i>Level I</i>	Evidence from meta-analyses of multiple randomized controlled trials or evidence from multiple randomized controlled trials
<i>Level II</i>	Evidence from at least one randomized controlled trial or evidence from multiple well-designed controlled studies without randomization
<i>Level III</i>	Evidence obtained from at least one other type of well-designed quasi-experimental study, or evidence obtained from well-designed, nonexperimental descriptive studies such as comparative studies, correlation studies, or case studies
<i>Level IV</i>	Expert committee reports or opinions and/or clinical experiences of respected authorities

Table 2 Classification of recommendation categories

<i>Grade A</i>	Treatment is strongly recommended if there is at least one piece of level I evidence indicating validity
<i>Grade B</i>	Treatment is recommended if there is at least one piece of level II evidence indicating validity
<i>Grade C1</i>	Treatment can be considered, but the evidence is insufficient; for example, there are several reports of level III evidence, which shows validity with generally consistent results
<i>Grade C2</i>	Treatment is not recommended without sufficient scientific evidence
<i>Grade D</i>	Treatment is not recommended because utility and effectiveness have not been shown and the treatment may be harmful

in two separate chapters. Lymph node dissection and laparoscopic surgery are described in detail. In addition, postoperative hormone adjuvant therapy is described in the chapter regarding post-treatment follow-up. Atypical endometrial hyperplasia is included in the chapter regarding fertility-sparing therapy. The chapter regarding treatment of trophoblastic disease is based on the third edition of the general rules for clinical and pathological management of trophoblastic diseases by Japan society of obstetrics and gynecology and the Japanese pathological society.

4. Basic policies in creating the guidelines

To create these guidelines, the Guidelines Formulation Committee and Evaluation Committee were independently established within the Committee for Treatment Guidelines for Uterine Body Neoplasms. The initial draft was created after a thorough evaluation. Opinions from within and outside the JSGO were incorporated into the final draft. The guidelines were published after approval by the JSGO. Much of the evidence that formed the basis for the Japanese guidelines was obtained from clinical trials in Western countries. However, given the differences between practice in Japan and other countries, the consensus regarding clinical practice in Japan took priority in the event of discrepancies. Wherever possible, high-level Japanese evidence was used to formulate these guidelines. The following items are assumed to underlie the basic policy of the guidelines:

- (1) These guidelines were created in accordance with the principles of evidence-based medicine, considered to be the international standard for creating clinical practice guidelines.

- (2) Searches were performed of data and literature published until December 2011, including Japanese and non-Japanese studies in Japan and overseas.
- (3) The collected evidence was evaluated for quality using the criteria of the Japan Society of Clinical Oncology and its Formulation Committee of Clinical Practice Guidelines for the Use of Anticancer Agents [4, 5]. However, some of the contents were modified in line with these guidelines (Table 1).
- (4) The strengths of the recommendations in our guidelines were also determined by the recommendation criteria of the Japan Society of Clinical Oncology and its Formulation Committee of Clinical Practice Guidelines for the Use of Anticancer Agents. These were modified while referring to the "Minds clinical practice guidelines 2007" [6] (Table 2).
- (5) The surgical staging criteria described in the 2013 edition were based on the surgical staging system developed in 2008 by the International Federation of Gynecology and Obstetrics (FIGO). In the text, we did not use clinical stage (JSOG 1983, FIGO 1982), but used a description 'considered to be stage X preoperatively' instead.
- (6) Therapy is often difficult to administer under the Japanese medical care insurance system. In this regard, the present guidelines follow the Formulation Committee of Clinical Practice Guidelines for the Use of Anticancer Agents.

5. Disclosure of information

These guidelines are published as a pamphlet and are shown on the homepage of JSGO to facilitate widespread use.

6. Responsibility for treatment

The JSGO bears the responsibility for the content and descriptions of these guidelines. However, the final decision to use these guidelines should be made by the individual user. Thus, the responsibility for the treatment outcomes should be directly attributed to the person in charge.

7. Revision

- (1) These guidelines are continuously being revised by the Committee for Treatment Guidelines for Uterine Body Neoplasms with medical advances and medical changes.
- (2) Newly accumulated evidence after publishing these guidelines is saved in a database.
- (3) Any associated information regarding clinical inconvenience occurring with the use of these guidelines is collected.
- (4) Revision work is conducted by the Guidelines Formulation Committee and Evaluation Committee based on new evidence and information. Opinions from associated academic societies, groups or JSGO members are widely gained.
- (5) After the above-mentioned process, the Committee for Treatment Guidelines for Uterine Body Neoplasms provides a revised version with the approval of the JSGO.

8. Funding

Preparation of these guidelines was funded by the JSGO. We also acknowledge support by grants from the Ministry of Health, Labour and Welfare and H24-Clinical Cancer Research-001 (chief researcher, Koichi Hirata). The expense incurred had no influence on the contents of these guidelines.

9. Conflicts of interest

The Board of the Society Conflict of Interest Committee confirmed the absence of any conflicts of interest. Although some committees had conflicts of interest through study or lecture activity with the company, the contents of these guidelines are based on scientific evidence and thus unaffected by any interest with specific groups or products.

10. Summary of recommendations

In general, each chapter comprises a clinical question (CQ), recommendations, background, objectives, explanations,

and references. This article summarizes the guidelines in a question-and-answer format. Recommendations from each chapter are listed below under their respective chapter titles.

11. Algorithms

These guidelines contain the following nine algorithms:

1. Initial treatment for patients with endometrial cancer considered to be stage I or II preoperatively (Fig. 1).
2. Initial treatment for patients who are confirmed as having endometrial cancer after hysterectomy (Fig. 2).
3. Initial treatment for patients with endometrial cancer considered to be stage III or IV preoperatively (Fig. 3).
4. Postoperative adjuvant treatment for endometrial cancer (Fig. 4, Table 3).
5. Treatment of recurrent endometrial cancer (Fig. 5).
6. Strategies for fertility-sparing therapy (atypical endometrial hyperplasia and endometrioid adenocarcinoma; corresponding to G1) (Fig. 6).
7. Treatment for uterine carcinosarcoma (Fig. 7).
8. Treatment for uterine sarcoma (Fig. 8).
9. Treatment for choriocarcinoma (Fig. 9).

Chapter 2: Initial treatment for endometrial cancer (including histologic variant type)

CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?

Recommendations:

1. Abdominal total hysterectomy (extrafascial technique) is recommended (Grade B).
2. Modified radical (extended) hysterectomy is also considered (Grade C1).

[See Fig. 1].

CQ02. Which surgical hysterectomy techniques are recommended for patients considered to be stage II?

Recommendations:

Either radical hysterectomy or modified radical hysterectomy should be considered for patients with clinically apparent cervical stromal involvement (Grade C1).

[See Fig. 1].




Fig. 1 Initial treatment for patients with endometrial cancer considered to be stage I or II preoperatively. **a** Radiation therapy or chemotherapy are considered when surgery is impossible. **b** Pelvic and para-aortic lymphadenectomy/lymph node biopsy and omentectomy are

considered in addition to total hysterectomy with bilateral salpingo-oophorectomy for patients with serous adenocarcinoma or clear-cell adenocarcinoma. *CQ* clinical question




Fig. 2 Initial treatment for patients who are confirmed as having endometrial cancer after hysterectomy. **a** Postoperative chemotherapy is considered for positive lymphovascular space invasion




Fig. 3 Initial treatment for patients with endometrial cancer considered to be stage III or IV preoperatively. **a** Because serous adenocarcinoma/clear cell adenocarcinoma is likely to become disseminated, the omentectomy is useful for a diagnosis. **b** Surgery is considered for the purpose of hemostasis even if there is extra-peritoneal metastasis or liver metastasis




Fig. 4 Postoperative adjuvant treatment for endometrial cancer

CQ03 What are the benefits of pelvic lymphadenectomy?

Recommendations:

1. The diagnostic significance of pelvic lymph node dissection in the determination of correct surgical staging has been established (Grade A).
2. The therapeutic benefits of pelvic lymphadenectomy are not established. However, this procedure should be considered in intermediate-risk or high-risk patients (Grade C1).

[See Fig. 1].

CQ04 What are the benefits of para-aortic lymphadenectomy (biopsy)?

Recommendations:

1. Para-aortic lymphadenectomy (biopsy) is necessary to determine correct surgical staging (Grade A).
2. The therapeutic benefits of para-aortic lymphadenectomy (lymph node biopsy) are not established. How-

Table 3 Classification of postoperative recurrence risk of endometrial cancer

Low-risk group
Endometrioid adenocarcinoma G1 or G2 and <1/2 myometrial invasion
No cervical involvement
No lymphovascular invasion
No distant metastasis
Intermediate-risk group
Endometrioid adenocarcinoma G1 or G2 and ≥1/2 myometrial invasion
Endometrioid adenocarcinoma G3 and <1/2 myometrial invasion
Serous adenocarcinoma, clear-cell adenocarcinoma and no myometrial invasion
No cervical involvement
Positive lymphovascular invasion
No distant metastasis
High-risk group
Endometrioid adenocarcinoma G3 and ≥1/2 myometrial invasion
Serous adenocarcinoma, clear-cell adenocarcinoma and myometrial invasion
Spread to the uterine adnexa, serosa, or cardinal ligament
Invasion of the vaginal wall
Pelvic or para-aortic lymph node metastasis
Vesical or rectal invasion
Peritoneal dissemination
Distant metastasis

There is the opinion to think that positive peritoneal cytology is a poor prognostic factor. (extracted from refs. [7, 8] with some modification)

ever, this procedure should be considered in intermediate-risk or high-risk patients (Grade C1).

[See Fig. 1].

CQ05 Is omentectomy necessary?

Recommendations:

1. Searching the omentum by careful ocular inspection and palpation is necessary in all cases. When metastasis is suspected, omentectomy should be performed to determine the correct stage (Grade A).
2. Omentectomy is considered when deep myometrial invasion, positive intraoperative peritoneal cytology, Grade 3 endometrial carcinoma, serous or clear cell adenocarcinoma, or macroscopic extrauterine disease is present, even if no gross abnormalities are detected in the omentum (Grade C1).

[See Fig. 1].

CQ06 Is ovarian preservation possible?

Recommendations:

1. In principle, bilateral adnexectomy is conducted to determine the correct surgical stage during initial treatment (Grade A).




Fig. 5 Treatment of recurrent endometrial cancer




Fig. 6 Strategies for fertility-sparing therapy (atypical endometrial hyperplasia and endometrioid adenocarcinoma; corresponding to G1)




Fig. 7 Treatment for uterine carcinosarcoma




Fig. 8 Treatment for uterine sarcoma. *LGESS* low-grade endometrial stromal sarcoma, *UES* undifferentiated endometrial sarcoma, *LMS* leiomyosarcoma

2. Ovarian preservation is considered after having explained the risks to young patients with well-differentiated tumors and shallow myometrial invasion (Grade C1).

[See Fig. 1].

CQ07 What surgical technique is recommended for serous adenocarcinoma and clear-cell adenocarcinoma?

Recommendations:

1. Total hysterectomy with bilateral salpingo-oophorectomy is recommended (Grade B).
2. Additionally, pelvic and para-aortic lymphadenectomy (lymph node biopsy) and omentectomy are considered (Grade C1).

[See Fig. 1].

CQ08 Is an inguinal lymph node biopsy noted in the surgical staging guidelines necessary?

Recommendations:

1. When an enlarged inguinal lymph node is detected in preoperative imaging such as a computed tomography (CT) scan, then a biopsy is recommended to determine the surgical stage (Grade A).
2. When an enlarged inguinal lymph node is not detected, the benefits of biopsy are not evident. Therefore, routine inguinal lymph node biopsy is not recommended (Grade C2).

[See Fig. 1].

CQ09 What is the significance of preoperative diagnostic imaging?

Recommendations:

1. Evaluation for myometrial invasion and cervical invasion by preoperative magnetic resonance imaging (MRI) is recommended (Grade A).
2. Evaluation for lymph node metastases or distant metastases by preoperative imaging such as CT scan or MRI is recommended (Grade C1).

[See Figs. 1, 3, and 6].




Fig. 9 Treatment for choriocarcinoma

CQ10 Is intraoperative frozen-section diagnosis useful to determine the optimal operative method?

Recommendations:

1. Intraoperative frozen-section diagnosis may be useful for predicting high-risk disease for which pelvic and para-aortic lymphadenectomy or omentectomy would be appropriate (Grade C1).
2. Intraoperative frozen-section diagnosis is not recommended for a definite diagnosis in terms of histological type, histologic differentiation, and myometrial invasion (Grade C2).

CQ11 Should intraoperative frozen-section diagnosis be performed to detect lymph node metastases?

Recommendations:

1. Intraoperative frozen-section diagnosis is useful in the diagnosis of metastasis when apparent lymph node enlargement is detected (Grade C1).
2. There is insufficient evidence to recommend modification of the surgical technique based on the lymph node metastasis status assessed with intraoperative frozen sections. It is not recommended in daily practice (Grade C2).

CQ12 Can lymphadenectomy be omitted if a sentinel node biopsy is performed?

Recommendations:

There is insufficient evidence to omit retroperitoneal lymphadenectomy (lymph node biopsy) based on the sentinel lymph node status. It is not recommended in daily practice (Grade C2).

CQ13 Should peritoneal cytology be performed at the same time as surgery?

Recommendations:

The performance of peritoneal cytology should be continued regardless of whether it is a prognostic factor. Positive cases should be reported separately from surgical staging (Grade A).

[See Figs. 1 and 3].

CQ14 Can laparoscopic surgery become a standard surgical technique?

Recommendations:

1. Laparoscopic surgery is considered for patients with atypical endometrial hyperplasia or an early endometrial cancer limited to the uterus (stage I) (Grade B).
2. Laparoscopic surgery is not recommended for patients with advanced endometrial cancer (Grade C2).

[See Fig. 1].

Additional statement

- It is advisable to decide upon the appropriate surgical procedure and to use a surgical team which includes a qualified surgeon of the Japan Society of Gynecologic and Obstetric Endoscopy and Minimally Invasive Therapy or the Japan Society for Endoscopic Surgery, and board-certified gynecologic oncologists of the JSGO. Otherwise, it is recommended that the surgery be performed according to the instructions of these physicians.
- The decision regarding the appropriate surgical procedure for laparoscopic surgery is carried out according to a basic policy described in CQ01, CQ03, and CQ04.

CQ15 How should patients be treated who are confirmed as having endometrial cancer after hysterectomy?

Recommendations:

1. Follow-up is possible when an extrauterine lesion is negative for myometrial invasion <1/2, G1, or G2. However, adjuvant therapy is considered when vascular invasion is detected (Grade C1).
2. Reoperation is considered when an extrauterine lesion is suspected or when G3, a variant histologic type, or stage >IB disease is present, even if myometrial invasion is <1/2. Based on the results, restaging is recom-

mended, metastasis is confirmed, and the necessity for adjuvant therapy should be discussed.

[See Fig. 2].

CQ16 What are the indications for definitive radiation therapy?

Recommendations:

Radiation therapy is considered when surgery is undesirable because of advanced age, complications, or when patients have unresectable tumors (Grade C1).

[See Fig. 3].

Chapter 3: Postoperative adjuvant therapy for endometrial cancer (including histologic variant type)**CQ17 What are the indications and drugs recommended for postoperative chemotherapy?**

Recommendations:

1. Chemotherapy with adriamycin (doxorubicin hydrochloride) and cisplatin is recommended for high-risk patients (Grade B).
2. Taxane-based and platinum-based drug combination therapy (e.g., paclitaxel/carboplatin) is also considered (Grade C1).
3. Postoperative adjuvant chemotherapy is considered for intermediate-risk patients (Grade C1).
4. Postoperative adjuvant chemotherapy is not recommended for low-risk patients (Grade D).

[See Figs. 2, 3 and 4].

CQ18 Is hormone therapy effective as postoperative adjuvant therapy?

Recommendations:

Postoperative progesterone therapy is not recommended (Grade D).

CQ19 What are the indications for postoperative whole-pelvis external-beam irradiation?

Recommendations:

1. Postoperative whole-pelvis external-beam irradiation is considered for patients with risk factors for recurrence (Grade C1).

2. Postoperative vaginal brachytherapy is considered to reduce the risk of vaginal recurrence (Grade C1).

[See Figs. 2, 3 and 4].

CQ20 What are the indications for postoperative irradiation of the para-aortic lymph node region and whole abdomen?

Recommendations:

1. Postoperative irradiation of the para-aortic lymph node region is considered for patients with advanced diseases (Grade C1).
2. Postoperative whole-abdominal irradiation may be used in patients with a variant histologic type, but it is not common in daily practice in Japan (Grade C2).

[See Figs. 2, 3 and 4].

Chapter 4: Post-treatment surveillance for endometrial cancer

CQ21 What intervals are recommended for post-treatment surveillance?

Recommendations:

Standard intervals between routine follow-up appointments are shown below (Grade C1):

1. Every 1–3 months for the first 1–3 years after treatment.
2. Every 6 months for the fourth and fifth years after treatment.
3. Annually from the sixth year after treatment.

[See Fig. 4].

CQ22 Should pelvic examinations and vaginal vault smears be performed at post-treatment follow-up?

Recommendations:

1. Pelvic examination should be performed to diagnose recurrence in the pelvis (Grade A).
2. Vaginal vault smears are considered to detect vaginal stump recurrence (Grade C1).

[See Fig. 4].

CQ23 Should serum tumor markers be measured at post-treatment follow-up?

Recommendations:

Measurement of CA-125 or CA19-9 is considered in post-treatment follow-up (Grade C1).

[See Fig. 4].

CQ24 Should diagnostic imaging be performed in post-treatment follow-up?

Recommendations:

1. Annual chest X-rays are considered for early detection of recurrence (Grade C1).
2. Diagnostic imaging methods such as MRI or CT scan are recommended when recurrence is clinically suspected (Grade B).

[See Fig. 4].

CQ25 Is hormone replacement therapy recommended after treatment?

Recommendations:

Hormone replacement therapy after treatment is carefully considered after having explained the advantages and disadvantages to the patient (Grade C1).

Chapter 5: Treatment for advanced or recurrent endometrial cancer

CQ26 What are the indications for surgery for clinical stages III and IV?

Recommendations:

Surgery is considered whenever a hysterectomy and cytoreduction are possible (Grade C1).

[See Fig. 3].

CQ27 Should neoadjuvant chemotherapy or preoperative radiation therapy be conducted for advanced cancer?

Recommendations:

1. Preoperative chemotherapy is considered in patients with peritoneal dissemination (Grade C1).

2. Preoperative radiation therapy may be conducted for patients with cervical invasion and enlargement; however, it is not common in daily practice in Japan (Grade C2).

[See Fig. 3].

CQ28 What are the indications for surgery for recurrent cancer?

Recommendations:

1. Surgical resection is considered for patients with pelvic recurrence without obvious distant metastasis (Grade C1).
2. Partial resection of the lung is also considered for patients with a few small lung metastases (Grade C1).

[See Fig. 5].

CQ29 Should chemotherapy be conducted for advanced cancer of imperfect resection and recurrent cancer?

Recommendations:

1. Chemotherapy is recommended (Grade B).
2. Paclitaxel/carboplatin, doxorubicin/cisplatin, or paclitaxel/doxorubicin/cisplatin is considered for patients with advanced diseases (Grade C1).
3. Paclitaxel/carboplatin, doxorubicin/cisplatin, or monotherapy is considered for patients with recurrent cancer by taking the situation of the patient and the initial treatment into consideration (Grade C1).

[See Figs. 3, 4, and 5].

CQ30 Should radiation therapy be conducted for recurrent and inoperable advanced cancer?

Recommendations:

1. Radiation therapy is recommended for patients with recurrence at the vaginal cuff (Grade B).
2. Radiation therapy is considered as a palliative option for recurrent cancer, unresectable advanced cancer, and metastatic cancer (Grade C1).

[See Figs. 3, 4, and 5].

CQ31 Should hormone therapy be conducted for advanced and recurrent cancer?

Recommendations:

Progesterone therapy is considered for patients with endometrioid adenocarcinoma (G1) and advanced or recurrent cancer with positive progesterone receptors (Grade C1).

[See Figs. 4 and 5].

Chapter 6: Fertility-sparing therapy

CQ32 When patients with atypical endometrial hyperplasia desire fertility preservation, is progesterone therapy recommended?

Recommendations:

Progesterone therapy is considered in patients with atypical endometrial hyperplasia (Grade C1).

[See Fig. 6].

CQ33 When patients with endometrioid adenocarcinoma (corresponding to G1) desire fertility preservation, is progesterone therapy recommended?

Recommendations:

Progesterone therapy is considered for patients with endometrioid adenocarcinoma (corresponding to G1) suspected to be confined to the endometrium (Grade C1).

[See Fig. 6].

CQ34 What are suitable follow-up periods and examinations?

Recommendations:

Endometrial biopsy and transvaginal ultrasonography are considered every 3 months after completion of progesterone therapy (Grade C1).

[See Fig. 6].

CQ35 What treatments are recommended for patients with recurrence after fertility preservation therapy?

Recommendations:

1. Total hysterectomy is recommended for patients with recurrent disease, an incomplete response, or progressive disease (Grade B).
2. The effectiveness of retreatment with progesterone has not been established in patients with recurrent disease. Retreatment with progesterone is not recommended in routine practice (Grade C2).

[See Fig. 6].

CQ36 Is ovulation induction permissible in patients after fertility preservation therapy?

Recommendations:

Induction of ovulation for pregnancy is considered (Grade C1).

[See Fig. 6].

Chapter 7: Treatment of uterine carcinosarcoma and uterine sarcoma**CQ37 What surgical techniques are recommended for uterine carcinosarcoma?**

Recommendations:

1. Total hysterectomy with bilateral salpingo-oophorectomy should be performed (Grade B).
2. In addition to the surgical method mentioned above, pelvic and para-aortic lymphadenectomy (biopsy) are recommended (Grade C1).
3. Radical hysterectomy or modified radical hysterectomy is considered for patients with obvious cervical stromal invasion in whom complete resection is anticipated (Grade C1).

[See Fig. 7].

CQ38 What postoperative adjuvant therapy is recommended for uterine carcinosarcoma?

Recommendations:

1. When postoperative chemotherapy is selected, regimens including ifosfamide, platinum-based drugs, and paclitaxel are considered (Grade C1).
2. Radiation therapy (whole-pelvis external-beam irradiation) is also considered (Grade C1).

[See Fig. 7].

CQ39 What treatments are recommended for advanced and recurrent uterine carcinosarcoma?

Recommendations:

1. If total hysterectomy and cytoreductive surgery are possible, surgical treatment is recommended (Grade C1).
2. Regimens including ifosfamide, platinum-based drugs, and paclitaxel are recommended for chemotherapy in

patients with advanced or recurrent disease (Grade C1).

[See Fig. 7].

CQ40 What surgical techniques and postoperative adjuvant therapy are recommended for uterine leiomyosarcoma?

Recommendations:

1. Complete extraction including total hysterectomy with bilateral salpingo-oophorectomy is recommended (Grade B).
2. Chemotherapy is considered as postoperative adjuvant therapy (Grade C1).
3. Postoperative radiation is less efficacious and is therefore not recommended in routine practice (Grade C2).

[See Fig. 8].

CQ41 What surgical techniques and postoperative adjuvant therapy are recommended for endometrial stromal sarcoma (ESS)?

Recommendations:

1. Total hysterectomy with bilateral salpingo-oophorectomy is recommended as a standard surgical procedure (Grade B).
2. Pelvic and para-aortic lymphadenectomy (biopsy) or cytoreductive surgery is also considered (Grade C1).
3. For stage I or II low-grade ESS, follow-up without postoperative adjuvant therapy is recommended (Grade B).
4. When adjuvant therapy is necessary for high-grade ESS, chemotherapy is recommended (Grade C1).

[See Fig. 8].

CQ42 What treatments are recommended for unresectable or recurrent ESS/leiomyosarcoma?

Recommendations:

1. Surgery is considered for recurrence if the tumor is resectable (Grade C1).
2. Chemotherapy is also considered (Grade C1).
3. Hormonal therapy is also considered for low-grade ESS (Grade C1).
4. Radiation therapy for the purpose of palliative care is considered (Grade C1).

[See Fig. 8].